Primaa SAS

Primaa SAS specializes in developing AI-powered diagnostic solutions for cancer, empowering healthcare professionals with advanced tools for accurate and efficient cancer diagnosis. Founded in 2018 in Paris, France, Primaa SAS is dedicated to enhancing cancer diagnostics. The company has engaged in 2 significant deals, with its latest funding round being a Series B in July 2022, raising EUR 2. 15 mn, which aligns with its valuation of EUR 10.

981 mn. The founders of Primaa are Fanny Massart, Marie Sockeel, and Stephane Sockeel, with Fanny Massart currently serving as CEO. Primaa's primary product offering is the Cleo platform, an AI-powered software solution designed to assist pathologists in cancer diagnosis, specializing in breast and skin cancer. Cleo utilizes advanced image analysis and deep learning technologies to detect various cancer biomarkers with a high degree of accuracy and speed.

This platform supports medical professionals by streamlining the diagnostic process, ultimately guiding personalized treatment plans for patients. Cleo has been validated through clinical studies and has received CE marking, allowing for commercialization across multiple European markets. Primaa primarily serves hospitals, diagnostic laboratories, and healthcare institutions, focusing on enhancing the efficiency and effectiveness of cancer diagnostics in regions such as France, Germany, and other European countries. Primaa operates under a revenue model that includes subscriptions and partnerships with healthcare providers and institutions leveraging its AI solutions.

The company engages in direct B2B transactions, where clients, including hospitals and diagnostic labs, integrate Cleo into their diagnostic workflows. This integration enhances their diagnostic capabilities and results in potential cost savings and improved patient outcomes. The structure of these transactions may involve tiered pricing plans based on the volume of cases processed or the specific features of the Cleo platform utilized by the client. By providing a sophisticated tool for cancer diagnostics, Primaa aims to establish long-term relationships with its clients, ensuring that medical professionals can maximize the benefits of AI technology in their practices.

In July 2022, Primaa raised EUR 2. 15 mn in venture funding, which will support its initiatives for future growth. The company is working on new features for the Cleo platform to enhance its diagnostic capabilities. Additionally, Primaa plans to expand its market reach into other European countries by 2024, aiming to increase the adoption of its AI diagnostic solutions across the continent.

In October 2025, Primaa SAS raised EUR 7 million in venture funding from new investors MH Innov, Elaia Partners, SWEN Capital Partners, and Super Capital VC. Individual investors also participated in the round. The company will use the October 2025 funding to support the growth of its sales organization and expansion plans initiatives.